Streamline Health® Reports Fiscal First Quarter 2025 Financial Results
- Total revenue increased 12% YoY to $4.8M
- SaaS revenue grew 23% YoY to $3.4M, representing 70% of total revenue
- Net loss improved to $1.6M from $2.7M YoY
- Adjusted EBITDA turned positive at $0.2M compared to -$0.7M loss YoY
- MDaudit to acquire Streamline at $5.34 per share, representing a 138% premium
- Cash and cash equivalents declined to $1.4M from $2.2M in January 2025
- Company experienced client non-renewals
- Higher interest expense impacted bottom line
Insights
Streamline shows improving financials with narrowing losses as it prepares to be acquired by MDaudit at a substantial premium.
Streamline Health's Q1 fiscal 2025 results reveal a company gaining operational momentum while simultaneously preparing for acquisition. Revenue increased
The company has significantly narrowed its net loss to
Cash position declined to
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fiscal first quarter of 2025 which ended April 30, 2025.
Fiscal First Quarter Financial Results
Total revenue for the first quarter of fiscal 2025 increased approximately
SaaS revenue for the first quarter of fiscal 2025 increased
Net loss for the first quarter of fiscal 2025 was (
Cash and cash equivalents as of April 30, 2025 was
Adjusted EBITDA for the first quarter of fiscal 2025 was
Definitive Merger Agreement with MDaudit
On May 29, 2025, the Company announced that it had entered into a definitive merger agreement pursuant to which MDaudit will acquire Streamline in an all-cash transaction valued at approximately
About Streamline
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Non-GAAP Financial Measures
Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.
Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, share-based compensation expense, significant non-recurring operating expenses, restructuring expenses, impairment of goodwill and long-lived assets and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related alignment expenses, associate inducements, and professional and advisory fees. A table reconciling this measure to “net loss,” to the extent relevant items were recognized in the periods covered, is included in this press release.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements contained in this press release include, without limitation, projections, predictions, expectations, or beliefs about future events or results and all other statements that are not statements of historical fact. Such statements may include statements regarding the closing of the proposed merger and the expected timing thereof, the expected value provided to stockholders as a result of the proposed merger, the management of the Company upon closing of the proposed merger, and the Company’s operating and strategic plans upon closing of the proposed merger. Such forward-looking statements are based on various assumptions as of the time they are made, all of which are subject to change, and are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are often accompanied by words that convey projected future events or outcomes such as “expect,” “believe,” “estimate,” “plan,” “project,” “anticipate,” “intend,” “will,” “may,” “view,” “opportunity,” “potential,” “aim,” “could,” “would,” “seek,” “might,” “considered,” “continue,” “target” or words of similar meaning or the negatives of these words or other statements concerning opinions or judgments of the Company or its management about future events or outcomes or that otherwise convey uncertainty about future events or outcomes. By their nature, forward-looking statements address matters that involve risks and uncertainties because they relate to events and depend upon future circumstances that may or may not occur, such as the closing of the merger and the anticipated benefits thereof. There can be no assurance that actual results, performance, or achievements of the Company will not differ materially from any projected future results, performance or achievements expressed or implied by such forward-looking statements or any related oral statements. Actual future results, performance or achievements may differ materially from historical results or those anticipated depending on a variety of factors, some of which are beyond the control of the Company, including, but not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; the inability to close the proposed merger due to the failure to obtain stockholder approval for the proposed merger or the failure to satisfy other conditions to closing of the proposed merger; risks related to disruption of management’s attention from the Company’s ongoing business operations due to the proposed merger; unexpected costs, charges or expenses resulting from the proposed merger; the Company’s ability to retain and hire key personnel; certain restrictions during the pendency of the proposed merger that may impact the company’s ability to pursue certain business opportunities or strategic transactions; the ability of the buyer to obtain necessary financing arrangements, if any; potential litigation relating to the proposed merger that could be instituted against the parties to the merger agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto; the effect of the announcement of the proposed merger on the Company’s relationships with its customers, operating results and business generally; continued availability of capital and financing and rating agency actions; legislative, regulatory and economic developments affecting the Company’s business; general economic and market developments and conditions; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, pandemics, outbreaks of war or hostilities, as well as the Company’s response to any of the aforementioned factors; significant transaction costs associated with the merger; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; and the risk that the proposed merger will not be consummated in a timely manner, if at all; the Company’s operating and strategic plans upon closing of the proposed merger; the Company’s growth prospects; anticipated bookings; recognition of revenue from SaaS contracts; anticipated cost savings from previously announced strategic restructuring; expected improved implementation timelines and lower expenses for our clients; industry trends and market growth; adjusted EBITDA; and success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; the inability to close the proposed merger due to the failure to obtain stockholder approval for the proposed merger or the failure to satisfy other conditions to closing of the proposed merger; risks related to disruption of management’s attention from the Company’s ongoing business operations due to the proposed merger; unexpected costs, charges or expenses resulting from the proposed merger; the Company’s ability to retain and hire key personnel; certain restrictions during the pendency of the proposed merger that may impact the company’s ability to pursue certain business opportunities or strategic transactions; the ability of the buyer to obtain necessary financing arrangements, if any; potential litigation relating to the proposed merger that could be instituted against the parties to the merger agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto; the effect of the announcement of the proposed merger on the Company’s relationships with its customers, operating results and business generally; continued availability of capital and financing and rating agency actions; legislative, regulatory and economic developments affecting the Company’s business; general economic and market developments and conditions; unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities, as well as the Company’s response to any of the aforementioned factors; significant transaction costs associated with the merger; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the risk that the proposed merger will not be consummated in a timely manner, if at all; the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto; the potential cancellation of existing contracts or clients not completing projects; achievement of a breakeven SaaS ARR run rate; the impact of competitive solutions and pricing; solution demand and market acceptance; new solution development and enhancement of current solutions; key strategic alliances with vendors and channel partners that resell the Company’s solutions; the ability of the Company to generate cash from operations; the availability of additional debt and equity financing to fund the Company’s ongoing operations; the ability of the Company to control costs; the effects of cost-containment measures implemented by the Company; availability of solutions from third party vendors; the healthcare regulatory environment; potential changes in legislation, regulation and government funding affecting the healthcare industry; healthcare information systems budgets; availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems; fluctuations in operating results; effects of critical accounting policies and judgments; changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities; changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally; the Company’s ability to maintain compliance with the terms of its credit facilities; and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission (the “SEC”).
Additional risk factors that could cause actual results to differ materially from expectations include, but are not limited to, the risks identified by the Company in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Form 10-K for the fiscal year ended January 31, 2025, as amended, and comparable sections of the Company’s Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC’s website at www.sec.gov. While the list of factors presented here and in such filings with the SEC is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on the Company or its business or operations. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on the Company’s financial condition, results of operations, credit rating or liquidity. Readers are cautioned not to rely on the forward-looking statements contained in this press release. Forward-looking statements and any related oral statements speak only as of the date they are made, and the Company does not undertake any obligation to update, revise or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Additional Information and Where to Find It
This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In connection with the proposed merger, the Company intends to file relevant materials with the SEC, including a proxy statement on Schedule 14A, the definitive version of which will be sent or provided to the Company’s stockholders. This communication is not a substitute for the proxy statement or any other document that the Company may file with the SEC or send to its stockholders in connection with the proposed merger. STOCKHOLDERS OF THE COMPANY ARE ADVISED TO READ THE PROXY STATEMENT AND ANY OTHER DOCUMENTS FILED BY THE COMPANY WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE BUSINESS TO BE CONDUCTED AT THE SPECIAL MEETING. All such documents, when filed, may be obtained free of charge at the SEC’s website (http://www.sec.gov). These documents, once available, and the Company’s other filings with the SEC also will be available free of charge on the Company’s website at www.streamlinehealth.net.
Participants in the Solicitation
The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s stockholders with respect to the proposed merger. Information about the Company’s directors and executive officers and their ownership of the Company’s common stock is set forth in Part III of the Company’s Amendment No. 2 to the Annual Report on Form 10-K/A for the fiscal year ended January 31, 2025, filed with the SEC on May 30, 2025. To the extent that such individual’s holdings of the Company’s common stock have changed since the amounts printed in Part III of the Company’s Amendment No. 2 to the Annual Report on Form 10-K/A for the fiscal year ended January 31, 2025, filed with the SEC on May 30, 2025, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Other information regarding the identity of the potential participants, and their direct or indirect interests in the proposed merger, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed merger. Free copies of these materials may be obtained as described in the preceding paragraph.
Company Contact
Jacob Goldberger
Vice President, Finance
303-887-9625
jacob.goldberger@streamlinehealth.net
| STREAMLINE HEALTH SOLUTIONS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (rounded to the nearest thousand dollars, except share and per share information) | ||||||||
| Three Months Ended April 30, | ||||||||
| 2025 | 2024 | |||||||
| Revenues: | ||||||||
| Software as a service | $ | 3,359,000 | $ | 2,723,000 | ||||
| Maintenance and support | 737,000 | 890,000 | ||||||
| Professional fees and licenses | 714,000 | 717,000 | ||||||
| Total revenues | 4,810,000 | 4,330,000 | ||||||
| Operating expenses: | ||||||||
| Cost of software as a service | 1,380,000 | 1,348,000 | ||||||
| Cost of maintenance and support | 32,000 | 42,000 | ||||||
| Cost of professional fees and licenses | 808,000 | 887,000 | ||||||
| Selling, general and administrative expense | 2,788,000 | 3,192,000 | ||||||
| Research and development | 903,000 | 1,111,000 | ||||||
| Total operating expenses | 5,911,000 | 6,580,000 | ||||||
| Operating loss | (1,101,000 | ) | (2,250,000 | ) | ||||
| Other (expense) income: | ||||||||
| Interest expense | (543,000 | ) | (465,000 | ) | ||||
| Valuation adjustments | — | (24,000 | ) | |||||
| Other | (1,000 | ) | — | |||||
| Loss before income taxes | (1,645,000 | ) | (2,739,000 | ) | ||||
| Income tax benefit | — | — | ||||||
| Net loss | $ | (1,645,000 | ) | $ | (2,739,000 | ) | ||
| Basic and Diluted Earnings Per Share: | ||||||||
| Net loss per common share – basic and diluted | $ | (0.40 | ) | $ | (0.71 | ) | ||
| Weighted average number of common shares – basic and diluted | 4,128,029 | 3,881,606 | ||||||
| STREAMLINE HEALTH SOLUTIONS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (rounded to the nearest thousand dollars, except share and per share information) | |||||||
April 30, 2025 | January 31, 2025 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 1,449,000 | $ | 2,183,000 | |||
| Accounts receivable, net of allowance for credit losses of | 4,184,000 | 1,585,000 | |||||
| Contract receivables | 637,000 | 1,571,000 | |||||
| Prepaid and other current assets | 310,000 | 438,000 | |||||
| Total current assets | 6,580,000 | 5,777,000 | |||||
| Non-current assets: | |||||||
| Property and equipment, net of accumulated amortization of | 45,000 | 49,000 | |||||
| Capitalized software development costs, net of accumulated amortization of | 4,778,000 | 4,850,000 | |||||
| Intangible assets, net of accumulated amortization of | 10,026,000 | 10,435,000 | |||||
| Goodwill | 13,276,000 | 13,276,000 | |||||
| Other | 1,122,000 | 1,192,000 | |||||
| Total non-current assets | 29,247,000 | 29,802,000 | |||||
| Total assets | $ | 35,827,000 | $ | 35,579,000 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,547,000 | $ | 1,541,000 | |||
| Accrued expenses | 1,626,000 | 1,921,000 | |||||
| Term loan, net of deferred financing costs | 7,277,000 | 7,709,000 | |||||
| Line of credit | 2,000,000 | 1,000,000 | |||||
| Notes payable, net of deferred financing costs | 4,703,000 | 4,415,000 | |||||
| Deferred revenues | 7,126,000 | 6,099,000 | |||||
| Acquisition earnout liability | 377,000 | 377,000 | |||||
| Total current liabilities | 24,656,000 | 23,062,000 | |||||
| Non-current liabilities: | |||||||
| Deferred revenues, less current portion | 116,000 | 240,000 | |||||
| Total non-current liabilities | 116,000 | 240,000 | |||||
| Total liabilities | 24,772,000 | 23,302,000 | |||||
| Commitments and contingencies – Note 8 | |||||||
| Stockholders’ equity: | |||||||
| Common stock, | 43,000 | 43,000 | |||||
| Additional paid in capital | 138,515,000 | 138,092,000 | |||||
| Accumulated deficit | (127,503,000 | ) | (125,858,000 | ) | |||
| Total stockholders’ equity | 11,055,000 | 12,277,000 | |||||
| Total liabilities and stockholders’ equity | $ | 35,827,000 | $ | 35,579,000 | |||
| STREAMLINE HEALTH SOLUTIONS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (rounded to the nearest thousand dollars) | ||||||||
| Three Months Ended April 30, | ||||||||
| 2025 | 2024 | |||||||
| Net loss | $ | (1,645,000 | ) | $ | (2,739,000 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 1,042,000 | 1,120,000 | ||||||
| Accrued interest expense - notes payable | 189,000 | 152,000 | ||||||
| Valuation adjustments | — | 24,000 | ||||||
| Share-based compensation expense | 430,000 | 499,000 | ||||||
| Changes in assets and liabilities: | ||||||||
| Accounts and contract receivables | (1,665,000 | ) | 17,000 | |||||
| Other assets | 66,000 | (100,000 | ) | |||||
| Accounts payable | 6,000 | (161,000 | ) | |||||
| Accrued expenses and other liabilities | (295,000 | ) | (262,000 | ) | ||||
| Deferred revenue | 903,000 | 251,000 | ||||||
| Net cash used in operating activities | (969,000 | ) | (1,199,000 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Capitalization of software development costs | (232,000 | ) | (232,000 | ) | ||||
| Net cash used in investing activities | (232,000 | ) | (232,000 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Repayment of bank term loan | (500,000 | ) | (250,000 | ) | ||||
| Repayment of line of credit | — | (1,500,000 | ) | |||||
| Proceeds from issuance of common stock | — | 100,000 | ||||||
| Proceeds from notes payable | — | 4,400,000 | ||||||
| Proceeds from line of credit | 1,000,000 | — | ||||||
| Payments of acquisition earnout liabilities | — | (447,000 | ) | |||||
| Payments for deferred financing costs | — | (16,000 | ) | |||||
| Repurchase of common shares to satisfy employee tax withholding | (33,000 | ) | (67,000 | ) | ||||
| Net cash provided by financing activities | 467,000 | 2,220,000 | ||||||
| Net decrease in cash and cash equivalents | (734,000 | ) | 789,000 | |||||
| Cash and cash equivalents at beginning of period | 2,183,000 | 3,190,000 | ||||||
| Cash and cash equivalents at end of period | $ | 1,449,000 | $ | 3,979,000 | ||||
| STREAMLINE HEALTH SOLUTIONS, INC. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (Unaudited, rounded to the nearest thousand dollars) | ||||||||
| Three Months Ended | ||||||||
| April 30, 2025 | April 30, 2024 | |||||||
| Adjusted EBITDA Reconciliation | ||||||||
| Net Loss | $ | (1,645 | ) | $ | (2,739 | ) | ||
| Interest expense | 543 | 465 | ||||||
| Depreciation and amortization | 875 | 1,017 | ||||||
| EBITDA | $ | (227 | ) | $ | (1,257 | ) | ||
| Share-based compensation expense | 430 | 499 | ||||||
| Non-cash valuation adjustments | — | 24 | ||||||
| Acquisition-related costs, severance, and transaction-related bonuses | 23 | 31 | ||||||
| Adjusted EBITDA | $ | 226 | $ | (703 | ) | |||
Source: Streamline Health Solutions, Inc.
FAQ
What was Streamline Health's (STRM) revenue growth in Q1 2025?
How much is MDaudit paying to acquire Streamline Health (STRM)?
What was Streamline Health's (STRM) net loss in Q1 2025?
What is the premium offered in the MDaudit-Streamline Health merger?
When is the MDaudit-Streamline Health (STRM) merger expected to close?
